uniQure (NASDAQ:QURE) VP Alexander Edward Kuta III Sells 2,306 Shares

uniQure (NASDAQ:QUREGet Rating) VP Alexander Edward Kuta III sold 2,306 shares of the firm’s stock in a transaction on Wednesday, September 21st. The stock was sold at an average price of $18.65, for a total value of $43,006.90. Following the completion of the transaction, the vice president now owns 92,890 shares of the company’s stock, valued at approximately $1,732,398.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Alexander Edward Kuta III also recently made the following trade(s):

  • On Thursday, July 28th, Alexander Edward Kuta III sold 27,358 shares of uniQure stock. The shares were sold at an average price of $25.00, for a total value of $683,950.00.
  • On Friday, July 22nd, Alexander Edward Kuta III sold 5,643 shares of uniQure stock. The shares were sold at an average price of $25.00, for a total value of $141,075.00.

uniQure Stock Performance

Shares of QURE traded down $0.29 during mid-day trading on Friday, hitting $17.30. 595,818 shares of the company’s stock were exchanged, compared to its average volume of 620,248. The firm has a market capitalization of $808.41 million, a P/E ratio of -7.02 and a beta of 1.08. uniQure has a fifty-two week low of $12.52 and a fifty-two week high of $36.55. The business’s 50 day moving average is $21.24 and its two-hundred day moving average is $18.26. The company has a current ratio of 10.84, a quick ratio of 10.78 and a debt-to-equity ratio of 0.21.

uniQure (NASDAQ:QUREGet Rating) last announced its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.12. uniQure had a negative net margin of 184.06% and a negative return on equity of 20.56%. The company had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $19.66 million. On average, equities analysts expect that uniQure will post -3.61 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. acquired a new position in uniQure in the 1st quarter valued at approximately $27,000. Captrust Financial Advisors increased its stake in shares of uniQure by 1,392.3% during the 2nd quarter. Captrust Financial Advisors now owns 1,940 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 1,810 shares during the last quarter. US Bancorp DE increased its stake in shares of uniQure by 108.2% during the 2nd quarter. US Bancorp DE now owns 1,978 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 1,028 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of uniQure by 152.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,038 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 1,231 shares during the last quarter. Finally, Covestor Ltd acquired a new position in uniQure in the 1st quarter valued at $50,000. Institutional investors own 86.46% of the company’s stock.

Analysts Set New Price Targets

QURE has been the subject of several recent analyst reports. Wells Fargo & Company cut their price target on uniQure from $34.00 to $24.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 9th. StockNews.com lowered uniQure from a “hold” rating to a “sell” rating in a research note on Wednesday, August 10th. Chardan Capital cut their price target on uniQure from $65.00 to $60.00 and set a “buy” rating for the company in a research note on Tuesday, August 9th. Finally, TheStreet lowered uniQure from a “c-” rating to a “d” rating in a research note on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.38.

About uniQure

(Get Rating)

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.

Recommended Stories

Insider Buying and Selling by Quarter for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.